8.00Open8.00Pre Close0 Volume0 Open Interest12.50Strike Price0.00Turnover0.00%IV-5.71%PremiumMay 17, 2024Expiry Date10.75Intrinsic Value100Multiplier-2DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type--Delta--Gamma0.16Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Reneo Pharmaceuticals Stock Discussion
NEWS
Reneo Pharmaceuticals and OnKure Announce Proposed Merger
Reneo Pharmaceuticals and OnKure announced a merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company focusing on advancing OnKure's precision medicines in oncology. The combined company is expected to have $120 million in cash resources at close, funding through 2026. OnKure's lead program, OKI-219, is in a Phase 1 clinical trial for solid tumors.
well..a kind of first green day anyway
No comment yet